Expertise in
5
conditions

Aslaug Helland

Oslo, NO 
Expertise in
5
conditions
Oslo, NO 
OverviewLocationsClinical Research

Overview

Aslaug Helland practices in Oslo, Norway. Helland is highly rated in 5 conditions, according to our data. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, Anal Cancer, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 183 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Oslo, Norway
Other Locations
Nydalen, 4950, Norway
St. Olav University Hospital
Trondheim, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2024
Intervention Type: Other
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies
Enrollment Status: Unknown
Publish Date: March 28, 2023
Intervention Type: Drug
Study Drug: AZD9291
Study Phase: Phase 2
View 2 Less Clinical Trials

183 Total Publications

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway.
Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway.
Journal: BJC reports
Published: May 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Helland's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile